Updates on Group B Streptococcus Screening and Prophylaxis

Group B Streptococcus (GBS), also known as Streptococcus agalactiae, remains an important cause of severe infection in newborns. Early-onset disease can develop during the first week of life, commonly after exposure to maternal GBS during labor or birth. Pneumonia, sepsis, and meningitis are among its most serious outcomes.

Screening and prevention have changed as clinicians have gained better evidence about colonization, antibiotic timing, allergy management, and neonatal observation. The central strategy remains identifying pregnancies at risk and providing effective intrapartum antibiotic prophylaxis (IAP), while avoiding unnecessary treatment before labor.

These issues fit closely with the scientific priorities of perinatal and neonatal medicine represented by the FAOPS 2020 archive, which documented a planned Tokyo congress focused on research, clinical practice, and international collaboration across Asian and Oceania perinatal societies.

Why GBS Prevention Still Matters

GBS commonly colonizes the gastrointestinal and genital tracts without causing symptoms. Colonization can be temporary, intermittent, or newly acquired, so a negative result earlier in pregnancy does not reliably predict status at delivery. Transmission usually occurs during labor or after rupture of membranes, although infection can occasionally occur before labor begins.

Early-onset GBS disease typically appears within the first 24 hours of life, though the clinical definition extends through the first six days. Infants may present with respiratory distress, temperature instability, poor feeding, lethargy, hypotension, or rapidly progressive sepsis. Prematurity, prolonged rupture of membranes, maternal fever, and a previous infant with GBS disease increase concern.

Late-onset disease occurs from seven through 89 days of life and is biologically different. Intrapartum antibiotics reduce early-onset disease but do not reliably prevent late-onset meningitis or bacteremia. Families and clinicians should therefore remain alert to fever, poor feeding, irritability, breathing difficulty, or unusual sleepiness after discharge.

Current Antenatal Screening Strategy

In the United States, the American College of Obstetricians and Gynecologists recommends universal vaginal-rectal culture screening at 36 0/7 through 37 6/7 weeks of gestation. This timing keeps the result relatively current through the usual delivery window. A swab should sample the lower vagina and rectum; a vaginal-only specimen is less complete.

Many health systems use a similar universal screening model, while others apply a risk-based approach or combine culture with molecular testing. Local policy matters because laboratory capacity, antibiotic resistance, birth patterns, and access to prenatal care vary across countries. Clinicians working across borders should follow the relevant national guideline rather than assume that one protocol fits every setting.

A positive prenatal culture indicates maternal colonization, not active maternal disease. It usually means that antibiotics should be given during labor, not that treatment is required weeks before birth. Antepartum eradication is unreliable because recolonization can occur, and routine treatment of an asymptomatic carrier before labor does not provide dependable neonatal protection.

When Intrapartum Antibiotics Are Indicated

The clearest indications for IAP are a positive antenatal GBS culture, GBS bacteriuria during the current pregnancy, or a previous infant who developed invasive GBS disease. GBS bacteriuria at any concentration reflects heavy colonization and also requires treatment of the urinary infection when clinically indicated. It remains an indication for prophylaxis in labor even if a later screening culture is negative.

If GBS status is unknown when labor begins, prophylaxis is generally recommended when recognized risk factors are present. These include preterm labor, preterm prelabor rupture of membranes, rupture of membranes lasting 18 hours or longer, and maternal intrapartum temperature of at least 38°C. Suspected intra-amniotic infection requires broad-spectrum treatment that includes appropriate GBS coverage, rather than a narrow prophylaxis regimen alone.

Penicillin G remains the preferred medication for patients without a serious beta-lactam allergy. Ampicillin is an accepted alternative in many protocols. For a patient with a penicillin allergy, the history should distinguish a low-risk reaction from anaphylaxis, angioedema, respiratory compromise, or severe cutaneous adverse reaction. Cefazolin is generally preferred for low-risk allergy histories, while clindamycin should be used only when the isolate is documented as susceptible. Vancomycin is reserved for high-risk allergy when clindamycin cannot be used.

Timing, Dosing, and Delivery Decisions

Antibiotics should begin as soon as practical after labor starts or membranes rupture when an indication is present. Four hours of exposure before birth is often described as optimal, but clinicians should not delay a medically necessary delivery solely to complete a four-hour interval. Even a shorter duration can provide some benefit, and every eligible patient should receive prophylaxis as early as feasible.

Dosing depends on the selected drug, maternal weight, renal function, allergy profile, and local protocol. Penicillin G is commonly administered with an initial intravenous dose followed by regular maintenance doses until birth. Institutions should maintain accessible order sets that reflect current national recommendations and antimicrobial stewardship principles.

Cesarean birth performed before labor begins and before rupture of membranes generally does not require GBS-specific IAP, regardless of colonization status. Routine cesarean surgical prophylaxis is a separate issue. Once labor or membrane rupture occurs, the indication must be reassessed, especially if birth is expected to be vaginal or if the clinical situation changes.

Documentation is part of prevention. The medical record should clearly state the screening result, allergy history, antibiotic given, start time, dose, membrane status, maternal temperature, and birth time. Accurate documentation helps pediatric teams decide whether newborn observation, laboratory evaluation, or empiric antibiotics are needed.

Newborn Assessment After Birth

A well-appearing term infant whose mother received adequate IAP can usually receive routine care, subject to local policy. When prophylaxis is absent or considered inadequate, management depends on gestational age, duration of membrane rupture, maternal temperature, the infant’s clinical condition, and the timing of birth.

Current neonatal approaches favor careful clinical observation and structured risk assessment for many well-appearing infants, rather than automatic laboratory testing or antibiotics for every exposure. For infants born at or beyond 35 weeks, some centers use multivariate early-onset sepsis calculators alongside serial examinations. Others use categorical algorithms. Both approaches require reliable vital-sign monitoring and prompt escalation when symptoms develop.

Infants younger than 35 weeks, those with clinical illness, or those exposed to suspected intra-amniotic infection may require blood cultures and empiric antimicrobial treatment. A complete blood count alone is not a dependable screening test for early-onset sepsis. Clinical deterioration should carry more weight than a reassuring initial laboratory result.

Parents should receive clear discharge information. They need to know which symptoms require urgent assessment and why a newborn may be observed in hospital for an extended period after inadequate prophylaxis or other risk factors. Communication is especially important when early discharge is being considered.

Screening Technologies and Regional Practice

Culture remains widely used because it is inexpensive, familiar, and supported by extensive outcome data. Its limitations include the waiting period for results, specimen collection errors, and changing colonization status. A culture obtained too early may no longer reflect status at delivery, while a missed appointment can leave labor teams without essential information.

Nucleic acid amplification tests, including polymerase chain reaction-based assays, can produce results more quickly and may help when prenatal screening is unavailable. However, test performance depends on specimen quality, laboratory resources, validation, and whether the assay detects all clinically relevant strains. A rapid test should complement a broader protocol rather than replace sound clinical judgment.

The expansion of antimicrobial resistance surveillance is also important. Clindamycin and erythromycin resistance among GBS isolates can limit alternatives for patients with severe penicillin allergy. Laboratories should report susceptibility results in a way that is readily visible to obstetric and neonatal teams, and clinicians should avoid choosing clindamycin solely because it appears in an older allergy order set.

Research is progressing toward maternal GBS vaccination, which could provide protection against both early- and late-onset disease through transplacental antibodies. No licensed maternal GBS vaccine has yet replaced screening and IAP in routine practice. Until vaccination becomes available and is incorporated into national programs, prevention depends on dependable prenatal records, appropriate antibiotic selection, and coordinated newborn care.

Practical Actions for Safer GBS Care

Successful prevention is a systems task involving antenatal clinics, laboratories, labor wards, pharmacies, and neonatal services. Hospitals can reduce missed opportunities by using electronic reminders near the screening window, standardizing allergy assessment, and reviewing cases of early-onset infection or missed prophylaxis.

Clinicians can strengthen bedside decisions by combining guideline knowledge with local epidemiology and individual clinical details. Useful actions include:

• Offer vaginal-rectal screening at the locally recommended gestational age.
• Record GBS bacteriuria and previous neonatal GBS disease prominently in the birth plan.
• Start indicated IAP promptly during labor without delaying urgent obstetric care.
• Confirm penicillin allergy severity before selecting cefazolin, clindamycin, or vancomycin.
• Use serial newborn examinations and an established sepsis pathway after birth.

International collaboration remains valuable because screening coverage, laboratory access, antimicrobial resistance, and neonatal resources differ widely throughout Asia and Oceania. The cancellation of the Tokyo meeting also demonstrated how quickly clinical education and travel-based collaboration can be disrupted; the cancellation lessons remain relevant to planning resilient education and communication systems.

Clinicians, educators, and perinatal teams can use these updates to review local GBS protocols, audit prophylaxis timing, and strengthen the handoff between maternity and newborn services. Consistent implementation of evidence-based screening and intrapartum prevention gives families the best available protection while research continues toward broader and longer-lasting solutions.